US2014163011A1PendingUtilityA1
Modulators of atp-binding cassette transporters
Est. expiryJun 24, 2024(expired)· nominal 20-yr term from priority
Inventors:Sara Sabina Hadida-RuahAnna HazlewoodPeter D.J. GrootenhuisFredrick Van GoorAshvani SinghJinglan ZhouJason Mccartney
A61P 7/00A61P 37/02A61P 3/06A61P 43/00A61P 5/14A61P 7/04A61P 7/10A61P 37/00A61P 5/10A61P 9/00A61P 3/10A61P 5/18A61P 7/12A61P 7/02A61P 5/16A61P 5/00A61P 37/06A61P 25/14A61P 25/00A61P 25/28A61P 25/16A61P 27/02A61P 31/00A61P 27/04A61P 35/00A61P 29/00A61P 3/00A61P 11/00A61P 13/12A61P 21/02A61P 1/00A61P 1/12A61P 13/02A61P 21/04A61P 17/00A61P 1/10A61P 19/00A61P 21/00A61P 11/08A61P 19/08C07D 209/42C07C 229/52C07C 271/20A61K 31/47A61K 45/06A61K 31/403C07C 311/39C07D 409/12C07C 2601/18C07C 217/80C07D 215/227C07D 223/16A61K 31/472C07C 68/02A61K 31/404A61K 31/04C07C 205/43C07D 209/04C07D 311/58C07C 215/76A61K 31/136C07D 401/14G01N 33/5035C07C 68/00C07D 213/73A61K 31/5415C07D 217/06C07D 209/12C07D 209/14G01N 2333/705C07C 211/52C07D 213/20C07D 215/38A61K 31/277A61K 31/4709C07D 401/12C07C 2603/74C07D 417/12C07C 311/08C07D 405/12A61K 8/4926C07C 213/02G01N 33/566A61K 31/27C07D 265/36C07C 215/28C07D 209/18C07D 279/16C07C 217/76A61K 31/44A61K 31/538C07C 255/58A61K 31/4747C07D 215/56C07C 217/84A61K 31/55C07D 215/233C07D 209/20C07D 209/08C07D 209/96C07C 2602/10A61K 31/4045C07D 217/04C07D 471/10A61K 31/265C07D 413/12C07C 209/00C07C 69/96C07C 201/08C07D 209/94G01N 33/48728C07C 2601/14C07C 211/17C07C 219/34G01N 33/6872C07C 205/11C07C 215/70C07C 215/78C07C 211/50C07C 205/58A61K 31/352
68
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 - 75 . (canceled)
76 . A pharmaceutical composition comprising:
a. a pharmacological agent capable of inducing or augmenting CFTR activity; b. N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide; and c. a pharmaceutically acceptable carrier, adjuvant or vehicle.
77 . The composition according to claim 76 , wherein the pharmacological agent capable of inducing or augmenting CFTR activity increases the amount of CFTR present at the cell surface.
78 . The composition according to claim 76 , wherein the pharmacological agent induces a hitherto absent CFTR activity.
79 . The composition according to claim 76 , wherein the pharmacological agent augments an existing residual CFTR activity.
80 . A method of treating cystic fibrosis in a patient, comprising the step of administering to said patient a composition according to claim 76 .
81 . The method according to claim 80 , wherein the pharmacological agent capable of inducing or augmenting CFTR activity increases the amount of CFTR present at the cell surface.
82 . The method according to claim 80 , wherein the pharmacological agent induces a hitherto absent CFTR activity.
83 . The method according to claim 80 , wherein the pharmacological agent augments an existing residual CFTR activity.
84 . The method according to claim 80 , wherein N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide is administered concurrently with, prior to, or subsequent to the pharmacological agent capable of inducing or augmenting CFTR activity.
85 . The method according to claim 84 , wherein N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide is administered concurrently with the pharmacological agent capable of inducing or augmenting CFTR activity.
86 . The method according to claim 84 , wherein N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide is administered prior or subsequent to the pharmacological agent capable of inducing or augmenting CFTR activity.
87 . A method of lessening the severity of cystic fibrosis in a patient, comprising the step of administering to said patient a composition according to claim 76 .
88 . The method according to claim 87 , wherein the pharmacological agent capable of inducing or augmenting CFTR activity increases the amount of CFTR present at the cell surface.
89 . The method according to claim 87 , wherein the pharmacological agent induces a hitherto absent CFTR activity.
90 . The method according to claim 87 , wherein the pharmacological agent augments an existing residual CFTR activity.
91 . The method according to claim 87 , wherein N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide is administered concurrently with, prior to, or subsequent to the pharmacological agent capable of inducing or augmenting CFTR activity.
92 . The method according to claim 91 , wherein N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide is administered concurrently with the pharmacological agent capable of inducing or augmenting CFTR activity.
93 . The method according to claim 91 , wherein N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide is administered prior or subsequent to the pharmacological agent capable of inducing or augmenting CFTR activity.
94 . A method of treating cystic fibrosis in a patient having residual CFTR activity that is induced or augmented using pharmacological methods or gene therapy, comprising the step of administering to said patient N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide in combination with said pharmacological method or gene therapy.
95 . The method according to claim 94 , wherein inducing or augmenting CFTR activity increases the amount of CFTR present at the cell surface.
96 . The method according to claim 94 , wherein the pharmacological methods or gene therapy induces a hitherto absent CFTR activity.
97 . The method according to claim 94 , wherein the pharmacological methods or gene therapy augments an existing residual CFTR activity.
98 . A method of lessening the severity of cystic fibrosis in a patient having residual CFTR activity that is induced or augmented using pharmacological methods or gene therapy, comprising step of administering to said patient N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide in combination with said pharmacological method or gene therapy.
99 . The method according to claim 98 , wherein inducing or augmenting CFTR activity increases the amount of CFTR present at the cell surface.
100 . The method according to claim 98 , wherein the pharmacological methods or gene therapy induces a hitherto absent CFTR activity.
101 . The method according to claim 98 , wherein the pharmacological methods or gene therapy augments an existing residual CFTR activity.
102 . A method of augmenting CFTR activity in a biological sample, comprising the step of contacting said biological sample with a composition according to claim 76 .
103 . The method according to claim 102 , wherein the pharmacological agent capable of inducing or augmenting CFTR activity increases the amount of CFTR present at the cell surface.
104 . The method according to claim 102 , wherein the pharmacological agent induces a hitherto absent CFTR activity.
105 . The method according to claim 102 , wherein the pharmacological agent augments an existing residual CFTR activity.Join the waitlist — get patent alerts
Track US2014163011A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.